Stock Price Quote

ASTEC LIFESCIENCES LTD.

NSE : ASTECBSE : 533138ISIN CODE : INE563J01010Industry : Pesticides & AgrochemicalsHouse : Godrej
BSE901.80-32.45 (-3.47 %)
PREV CLOSE ( ) 934.25
OPEN PRICE ( ) 936.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2333
TODAY'S LOW / HIGH ( )896.00 936.65
52 WK LOW / HIGH ( )826.15 1487.65
NSE906.00-28.3 (-3.03 %)
PREV CLOSE( ) 934.30
OPEN PRICE ( ) 936.00
BID PRICE (QTY) 906.00 (6)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 22754
TODAY'S LOW / HIGH( ) 894.05 937.95
52 WK LOW / HIGH ( )825.05 1474.4
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 25-01 1994
Management Info
Nadir B Godrej - Chairman - Managing Director
Registered Office

Address Godrej One, 3rd Floor,Pirojshanagar, Eastern Express Highway ,Vikhroli (East),
Mumbai,
Maharashtra-400079

Phone 022-25188010

Email astecinfo@godrejastec.com

Website www.godrejastec.com

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE, NSE

NEWS

28Jan Astec Lifesciences gets nod for equity
Astec Lifesciences has received approval from Board of Directors for equ..
28Jan Astec Lifesciences climbs on getting n
Astec Lifesciences is currently trading at Rs. 947.95, up by 31.45 point..
08Jan Updates on Open Offer
Kotak Mahindra Capital Company Ltd ("Manager to the Offer") has submitte..
11Dec Updates on Open Offer
Kotak Mahindra Capital Company Ltd ("Manager to the Offer") has submitte..
03Dec Clarification Regarding Intimation Of
Kindly find enclosed the clarification regarding Intimation of Cessation..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit-404-469.87
Gross Profit -251.84 -618.76
Operating Profit -38.45-3.1899999999996
Net Sales 938.584581.81

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

3B Blackbio Dx (BSE)
peergroup  2005.60 (3.23%)
M.Cap ( in Cr)1721.34
Excel Industries (BSE)
peergroup  1373.60 (1.35%)
M.Cap ( in Cr)1726.71
Dhanuka Agritech (BSE)
peergroup  1486.45 (1.20%)
M.Cap ( in Cr)6774.99
BASF India (BSE)
peergroup  4350.50 (0.39%)
M.Cap ( in Cr)18831.42
Shivalik Rasayan (BSE)
peergroup  750.00 (1.67%)
M.Cap ( in Cr)1167.03

Shareholding Pattern

PROMOTERS 66.75%
MUTUAL FUNDS/UTI 4%
NON-INSTITUTION 27.42%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Astec Lifesciences Ltd.

Astec Lifesciences Ltd. was incorporated in the year 1994. Its today's share price is 901.8. Its current market capitalisation stands at Rs 1768.55 Cr. In the latest quarter, company has reported Gross Sales of Rs. 4592.64 Cr and Total Income of Rs.4637.64 Cr. The company's management includes Ganapati Dadasaheb Yadav, Anjali Gupte, Nandkumar Dhekne, RR Govindan, Burjis Godrej, Balram Singh Yadav, Ashok V Hiremath, Nadir B Godrej, Tejashree Pradhan.

It is listed on the BSE with a BSE Code of 533138 , NSE with an NSE Symbol of ASTEC and ISIN of INE563J01010. It's Registered office is at Godrej One, 3rd Floor,Pirojshanagar, Eastern Express Highway ,Vikhroli (East)Mumbai-400079, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, PM Kathariya & Co, Shah & Kathariya

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.